Xbrane Gets US Setback For Ranibizumab Filing

BLA For Biosimilar Lucentis Rival Withdrawn As FDA Asks For More Information

 
• By David Wallace
Sign outside of FDA's headquarters in White Oak, MD
The FDA has requested more information on the Xlucane filing • Source: Alamy

More from Biosimilars

More from Products